Akeso Files for China Approval of PD-1/CTLA-4 for Cervical Cancer

Akeso reported an NDA for its self-developed PD-1/CTLA-4 bi-specific antibody has been accepted for review in China under priority status. The company said cadonilimab is the first bi-specific antibody drug in the world to submit an NDA. In a pivotal Phase II trial, Akeso tested cadonilimab as a second line therapy in patients with relapsed or metastatic cervical cancer. One month ago, Akeso and its partner, Sino Bio were approved to launch their partnered anti-PD-1 injection in  China  for classic Hodgkin's lymphoma. More details.... Stock Symbols: (HK: 9926) (HK: 1177) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.